Bulls vs Bears
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
$14.19
0.886.61%
At close: -
$14.19
0.000.00%
After Hours: May 16, 4:42 PM EDT
Comments
Loading...
RxSight Analyst Ratings and Price Targets | NASDAQ:RXST | Benzinga
RxSight Inc has a consensus price target of $38.27 based on the ratings of 11 analysts. The high is $73 issued by BTIG on July 15, 2024. The low is $16 issued by UBS on April 9, 2025. The 3 most-recent analyst ratings were released by Piper Sandler, UBS, and Wells Fargo on April 15, 2025, April 9, 2025, and April 7, 2025, respectively. With an average price target of $17 between Piper Sandler, UBS, and Wells Fargo, there's an implied 19.80% upside for RxSight Inc from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
Piper Sandler
UBS
Wells Fargo
JP Morgan
Needham
1calculated from analyst ratings
Analyst Ratings for RxSight
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 04/15/2025 | Buy Now | 26.85% | Piper Sandler | Adam Maeder62% | → $18 | Initiates | → Neutral | Get Alert |
| 04/09/2025 | Buy Now | 12.76% | UBS | Danielle Antalffy60% | $45 → $16 | Downgrade | Buy → Neutral | Get Alert |
| 04/07/2025 | Buy Now | 19.8% | Wells Fargo | Larry Biegelsen67% | $22 → $17 | Maintains | Equal-Weight | Get Alert |
| 04/04/2025 | Buy Now | 19.8% | JP Morgan | Robbie Marcus67% | $40 → $17 | Downgrade | Overweight → Underweight | Get Alert |
| 04/03/2025 | Buy Now | 55.04% | Wells Fargo | Larry Biegelsen67% | $35 → $22 | Maintains | Equal-Weight | Get Alert |
| 04/03/2025 | Buy Now | 203.03% | Needham | David Saxon56% | $43 → $43 | Reiterates | Buy → Buy | Get Alert |
| 03/21/2025 | Buy Now | 153.7% | B of A Securities | Craig Bijou77% | $60 → $36 | Maintains | Buy | Get Alert |
| 03/19/2025 | Buy Now | 97.32% | Stifel | Thomas Stephan40% | $33 → $28 | Maintains | Hold | Get Alert |
| 02/26/2025 | Buy Now | 181.89% | JP Morgan | Robbie Marcus67% | $62 → $40 | Maintains | Overweight | Get Alert |
| 02/26/2025 | Buy Now | 132.56% | Stifel | Thomas Stephan40% | $35 → $33 | Maintains | Hold | Get Alert |
| 02/26/2025 | Buy Now | 146.65% | Wells Fargo | Larry Biegelsen67% | $40 → $35 | Maintains | Equal-Weight | Get Alert |
| 02/26/2025 | Buy Now | 203.03% | Needham | David Saxon56% | $43 → $43 | Reiterates | Buy → Buy | Get Alert |
| 01/13/2025 | Buy Now | 181.89% | Wells Fargo | Larry Biegelsen67% | $42 → $40 | Maintains | Equal-Weight | Get Alert |
| 01/13/2025 | Buy Now | 146.65% | Stifel | Thomas Stephan40% | $40 → $35 | Maintains | Hold | Get Alert |
| 01/13/2025 | Buy Now | 365.12% | Needham | David Saxon56% | $66 → $66 | Reiterates | Buy → Buy | Get Alert |
| 12/20/2024 | Buy Now | 181.89% | Stifel | Thomas Stephan40% | $65 → $40 | Downgrade | Buy → Hold | Get Alert |
| 12/17/2024 | Buy Now | 365.12% | Needham | David Saxon56% | $66 → $66 | Reiterates | Buy → Buy | Get Alert |
| 12/11/2024 | Buy Now | 195.98% | Wells Fargo | Larry Biegelsen67% | $56 → $42 | Downgrade | Overweight → Equal-Weight | Get Alert |
| 12/06/2024 | Buy Now | 266.46% | UBS | Danielle Antalffy60% | → $52 | Initiates | → Buy | Get Alert |
| 10/29/2024 | Buy Now | 407.4% | Jefferies | Young Li22% | → $72 | Initiates | → Buy | Get Alert |
| 09/13/2024 | Buy Now | 365.12% | Needham | David Saxon56% | $66 → $66 | Reiterates | Buy → Buy | Get Alert |
| 08/20/2024 | Buy Now | 365.12% | Needham | David Saxon56% | $54 → $66 | Maintains | Buy | Get Alert |
| 08/06/2024 | Buy Now | 280.55% | Wells Fargo | Larry Biegelsen67% | $68 → $54 | Maintains | Overweight | Get Alert |
| 08/06/2024 | Buy Now | 358.07% | Stifel | Thomas Stephan40% | $70 → $65 | Maintains | Buy | Get Alert |
| 08/06/2024 | Buy Now | 358.07% | Oppenheimer | Steven Lichtman62% | $72 → $65 | Maintains | Outperform | Get Alert |
| 08/06/2024 | Buy Now | 280.55% | Needham | David Saxon56% | $75 → $54 | Maintains | Buy | Get Alert |
| 07/15/2024 | Buy Now | 414.45% | BTIG | Ryan Zimmerman71% | $72 → $73 | Maintains | Buy | Get Alert |
| 07/10/2024 | Buy Now | 393.31% | Stifel | Thomas Stephan40% | $75 → $70 | Maintains | Buy | Get Alert |
| 05/07/2024 | Buy Now | 379.21% | Wells Fargo | Larry Biegelsen67% | $61 → $68 | Maintains | Overweight | Get Alert |
| 05/07/2024 | Buy Now | 407.4% | Oppenheimer | Steven Lichtman62% | $61 → $72 | Maintains | Outperform | Get Alert |
| 05/07/2024 | Buy Now | 428.54% | Needham | David Saxon56% | $64 → $75 | Maintains | Buy | Get Alert |
| 05/07/2024 | Buy Now | 407.4% | BTIG | Ryan Zimmerman71% | $61 → $72 | Maintains | Buy | Get Alert |
| 05/06/2024 | Buy Now | 379.21% | Stifel | Thomas Stephan40% | $64 → $68 | Maintains | Buy | Get Alert |
| 04/11/2024 | Buy Now | 351.02% | Needham | David Saxon56% | $64 → $64 | Reiterates | Buy → Buy | Get Alert |
| 02/29/2024 | Buy Now | 351.02% | Stifel | Thomas Stephan40% | $54 → $64 | Maintains | Buy | Get Alert |
| 02/29/2024 | Buy Now | 336.93% | JP Morgan | Robbie Marcus67% | $40 → $62 | Maintains | Overweight | Get Alert |
| 02/29/2024 | Buy Now | 329.88% | Oppenheimer | Steven Lichtman62% | $54 → $61 | Maintains | Outperform | Get Alert |
| 02/29/2024 | Buy Now | 351.02% | Needham | David Saxon56% | $53 → $64 | Maintains | Buy | Get Alert |
| 02/12/2024 | Buy Now | 280.55% | Stifel | Thomas Stephan40% | $45 → $54 | Maintains | Buy | Get Alert |
| 01/29/2024 | Buy Now | 280.55% | Oppenheimer | Steven Lichtman62% | $50 → $54 | Maintains | Outperform | Get Alert |
| 01/16/2024 | Buy Now | 252.36% | Oppenheimer | Steven Lichtman62% | $46 → $50 | Maintains | Outperform | Get Alert |
| 01/08/2024 | Buy Now | 188.94% | Needham | David Saxon56% | $35 → $41 | Maintains | Buy | Get Alert |
| 01/08/2024 | Buy Now | 224.17% | Oppenheimer | Steven Lichtman62% | $38 → $46 | Maintains | Outperform | Get Alert |
| 12/13/2023 | Buy Now | 195.98% | Wells Fargo | Larry Biegelsen67% | → $42 | Upgrade | Equal-Weight → Overweight | Get Alert |
| 12/12/2023 | Buy Now | 181.89% | Stifel | Thomas Stephan40% | → $40 | Initiates | → Buy | Get Alert |
| 12/04/2023 | Buy Now | 153.7% | Morgan Stanley | Patrick Wood51% | → $36 | Initiates | → Overweight | Get Alert |
| 11/10/2023 | Buy Now | 111.42% | Needham | David Saxon56% | $36 → $30 | Maintains | Buy | Get Alert |
| 08/08/2023 | Buy Now | 139.61% | Oppenheimer | Steven Lichtman62% | $29 → $34 | Maintains | Outperform | Get Alert |
| 08/08/2023 | Buy Now | 139.61% | Needham | David Saxon56% | → $34 | Reiterates | Buy → Buy | Get Alert |
| 07/12/2023 | Buy Now | 139.61% | Needham | David Saxon56% | $27 → $34 | Maintains | Buy | Get Alert |
| 06/05/2023 | Buy Now | 104.37% | BTIG | Ryan Zimmerman71% | $25 → $29 | Maintains | Buy | Get Alert |
| 06/05/2023 | Buy Now | 90.27% | Wells Fargo | Larry Biegelsen67% | $17 → $27 | Maintains | Equal-Weight | Get Alert |
| 05/10/2023 | Buy Now | 90.27% | Needham | David Saxon56% | $22 → $27 | Maintains | Buy | Get Alert |
| 05/10/2023 | Buy Now | 19.8% | Wells Fargo | Larry Biegelsen67% | $15 → $17 | Maintains | Equal-Weight | Get Alert |
| 04/19/2023 | Buy Now | 55.04% | Needham | David Saxon56% | → $22 | Maintains | Buy | Get Alert |
| 04/13/2023 | Buy Now | 62.09% | Oppenheimer | Steven Lichtman62% | → $23 | Initiates | → Outperform | Get Alert |
| 03/07/2023 | Buy Now | 40.94% | JP Morgan | Robbie Marcus67% | $22 → $20 | Maintains | Overweight | Get Alert |
| 03/07/2023 | Buy Now | 55.04% | Needham | David Saxon56% | → $22 | Reiterates | → Buy | Get Alert |
| 03/03/2023 | Buy Now | 55.04% | Needham | David Saxon56% | → $22 | Reiterates | → Buy | Get Alert |
| 02/07/2023 | Buy Now | 55.04% | Needham | David Saxon56% | → $22 | Reiterates | → Buy | Get Alert |
| 12/12/2022 | Buy Now | -1.34% | Wells Fargo | Larry Biegelsen67% | $20 → $14 | Downgrade | Overweight → Equal-Weight | Get Alert |
| 08/09/2022 | Buy Now | 55.04% | Needham | David Saxon56% | $19 → $22 | Maintains | Buy | Get Alert |
FAQ
What is the target price for RxSight (RXST) stock?
The latest price target for RxSight (NASDAQ:RXST) was reported by Piper Sandler on April 15, 2025. The analyst firm set a price target for $18.00 expecting RXST to rise to within 12 months (a possible 26.85% upside). 28 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for RxSight (RXST)?
The latest analyst rating for RxSight (NASDAQ:RXST) was provided by Piper Sandler, and RxSight initiated their neutral rating.
When was the last upgrade for RxSight (RXST)?
The last upgrade for RxSight Inc happened on December 13, 2023 when Wells Fargo raised their price target to $42. Wells Fargo previously had an equal-weight for RxSight Inc.
When was the last downgrade for RxSight (RXST)?
The last downgrade for RxSight Inc happened on April 9, 2025 when UBS changed their price target from $45 to $16 for RxSight Inc.
When is the next analyst rating going to be posted or updated for RxSight (RXST)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of RxSight, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for RxSight was filed on April 15, 2025 so you should expect the next rating to be made available sometime around April 15, 2026.
Is the Analyst Rating RxSight (RXST) correct?
While ratings are subjective and will change, the latest RxSight (RXST) rating was a initiated with a price target of $0.00 to $18.00. The current price RxSight (RXST) is trading at is $14.19, which is within the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.
